Endpoints News· @endpts · X·· 2 小时前精选AI 评分78
AI 导读
罗氏旗下乳腺癌口服药Wilserdly获FDA批准用于晚期疾病,比原定时间提前一个多月。该药属于SERD类药物,罗氏由此进入这一治疗赛道。
推荐理由
罗氏的乳腺癌口服药提前一个多月获FDA批准,读者可据此了解SERD赛道的竞争节奏。
正文
Roche entered the SERD market with FDA approval of its breast cancer pill Wilserdly in late-stage disease, more than a month early. https://endpoints.news/roche-enters-the-serd-market-with-fda-approval-in-late-stage-breast-cancer/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com